Rhinitis causing the rhinitis. Rhinitis medicamentosa is a form of drug-induced nonallergic rhinitis which is associated with nasal congestion brought on by the use of certain oral medications (primarily sympathomimetic amine and 2-imidazoline derivatives) and topical decongestants (e.g., oxymetazoline, phenylephrine, xylometazoline, and naphazoline nasal sprays) that constrict the blood vessels in the lining of the nose. Chronic rhinitis is a form of atrophy of the mucous membrane and glands of the nose. Chronic form of dryness of the mucous membranes. Chronic rhinitis associated with polyps in the nasal cavity. Most prominent pathological changes observed are nasal airway epithelial metaplasia in which
Nasal EPAP obstruction. Side effects that emerged during clinical trials included difficulty breathing, difficulty falling or staying asleep, dry mouth, nasal congestion, headache, difficulty putting on or removing the device, and anxiety. Ventus Medical received FDA 510K clearance for marketing the Provent EPAP device for OSA in 2009. Ventus received 510K clearance for an EPAP device to treat snoring in June 2012. Ventus was acquired by Theravent Inc. in 2013. Calik MW. Treatments for Obstructive Sleep Apnea. J Clin Outcomes Manag. 2016 Apr;23(4):181-192. Nasal EPAP Nasal expiratory positive airway pressure (Nasal EPAP) is a treatment for obstructive sleep apnea (OSA) and snoring.